EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of Serum Autotaxin for Hepatocellular Carcinoma Recurrence After Curative Radiofrequency Ablation

Takanobu Iwadare, Hiroyuki Kobayashi, Takefumi Kimura iD, Taiki Okumura, Taro Nakajima, Shun-Ichi Wakabayashi, Yuki Yamashita, Naoyuki Fujimori, Hideo Kunimoto, Satoshi Shimamoto, Koji Igarashi, Takuro Uchida iD und 2 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Takanobu Iwadare und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Nagano, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Phosphoric Diester Hydrolases, Neoplasm Recurrence, Local. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, the Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite recent treatment advancements, the high recurrence rate of hepatocellular carcinoma (HCC) following curative therapy remains a significant challenge. Autotaxin (ATX) is a key biomarker in chronic liver disease that has a yet unclarified role in predicting HCC recurrence. This study examined whether precurative radiofrequency ablation (RFA) serum ATX level could serve as a predictor of HCC recurrence after treatment.

Methods

Fifty‐six HCC patients (37 [66%] male; median age: 74 years) treated by curative RFA were retrospectively analyzed.

Results

Twenty‐one patients experienced HCC recurrence during follow‐up. ATX demonstrated superior predictive performance for HCC recurrence after RFA, with an area under the receiver operating characteristic curve of 0.729, sensitivity of 0.857, and specificity of 0.629. Kaplan–Meier analysis revealed that patients with high ATX had a significantly higher incidence of HCC recurrence than those with low ATX ( p = 0.0006). In univariate analysis, the significant predictors of HCC recurrence included ATX (≥ 1.323 mg/L; hazard ratio [HR]: 6.49; 95% confidence interval [CI]: 1.90–22.13; p = 0.003), fibrosis‐4 index (≥ 3.524; HR: 2.75; 95% CI: 1.00–7.55; p = 0.050), and mac‐2 binding protein glycosylation isomer (≥ 3.85; HR: 2.12; 95% CI: 1.08–4.19; p = 0.030). According to multivariate Cox proportional hazards analysis with seven different models adjusting for age and various established biomarkers, ATX consistently emerged as the only significant independent predictor of HCC recurrence, with HR values ranging from 6.38 to 10.50 (all p < 0.05).

Conclusion

Serum ATX is a promising biomarker for predicting HCC recurrence post‐RFA treatment that may outperform conventional markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularPhosphoric Diester HydrolasesNeoplasm Recurrence, LocalRadiofrequency AblationBiomarkers, TumorHumansMaleAgedFemaleLysophospholipase DMiddle AgedRetrospective StudiesPrognosisKaplan-Meier EstimateAged, 80 and overROC Curve

Stichwörter der Autor:innen

autotaxinbiomarkerhepatocellular carcinomaradiofrequency ablationrecurrence

Substanzen

Phosphoric Diester HydrolasesLysophospholipase DBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Nagano, Japan.
  • Consultation Center for Liver Diseases, Shinshu University Hospital, Nagano, Japan.
  • Department of Hepatology, Shinshu Ueda Medical Center, Nagano, Japan.
  • Department of Hepatology, Nagano Municipal Hospital, Nagano, Nagano, Japan.
  • Bioscience Division, TOSOH Corporation, Ayase, Kanagawa, Japan.
  • Division of Travel Medicine and Health, Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Yufu, Oita, Japan.

ORCID-Profile: Takefumi Kimura, Takuro Uchida, Takeji Umemura, Naoki Tanaka

Förderung

  • Japan Agency for Medical Research and Development
  • the Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University
  • Japan Society for the Promotion of Science

Zitieren

APA

Iwadare, T., Kobayashi, H., Kimura, T., Okumura, T., Nakajima, T., Wakabayashi, S. I., Yamashita, Y., Fujimori, N., Kunimoto, H., Shimamoto, S., Igarashi, K., Uchida, T., Umemura, T., & Tanaka, N. (2026). Predictive Value of Serum Autotaxin for Hepatocellular Carcinoma Recurrence After Curative Radiofrequency Ablation. Cancer Medicine. https://doi.org/10.1002/cam4.71506

Vancouver

Iwadare T, Kobayashi H, Kimura T, Okumura T, Nakajima T, Wakabayashi SI, et al. Predictive Value of Serum Autotaxin for Hepatocellular Carcinoma Recurrence After Curative Radiofrequency Ablation. Cancer Medicine. 2026. doi:10.1002/cam4.71506

BibTeX
@article{Iwadare2026,
  author = {Iwadare, Takanobu and Kobayashi, Hiroyuki and Kimura, Takefumi and Okumura, Taiki and Nakajima, Taro and Wakabayashi, Shun-Ichi and Yamashita, Yuki and Fujimori, Naoyuki and Kunimoto, Hideo and Shimamoto, Satoshi and Igarashi, Koji and Uchida, Takuro and Umemura, Takeji and Tanaka, Naoki},
  title = {Predictive Value of Serum Autotaxin for Hepatocellular Carcinoma Recurrence After Curative Radiofrequency Ablation},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71506}
}
Kostenlos starten →